A DNA vaccine targeting the breast cancer-associated antigen mammaglobin-A was proven safe and found to effectively elicit immune responses in women with metastatic breast cancer, according to a new study.
The possibilities for personalized vaccines in all types of cancer were explored at the European Society for Medical Oncology Symposium on Immuno-Oncology 2014.
An experimental breast cancer vaccine boosts immune response and appears to slow spread in those with advanced disease.
Results of a phase I clinical trial of a vaccine therapy for pancreatic cancer indicate the treatment is well tolerated; in addition, it suggests that the vaccine stabilizes the disease for a period of time.
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
In a new study, researchers examined the largest collection of tumor samples to date to predict patient-specific tumor mutations that may activate the patient’s immune system, paving the way for more successful, personalized cancer immunotherapy.
A novel DNA vaccine is being employed to kill cancer, not by attacking tumor cells, but by targeting the blood vessels that keep them alive.
Early progress has been made in developing a treatment that might one day help the immune system defend itself against cancer, but research is still in preliminary stages.
A protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates immune functions was found to prolong survival in animal models for ovarian cancer and mesothelioma.
Women vaccinated with one dose of a HPV vaccine had antibodies against the viruses that remained stable in their blood for 4 years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses against new HPV infections, and ultimately cervical cancer.
